Exploring the technologies and approaches shaping the modern drug discovery continuum

As drug discovery undergoes rapid transformation, driven by advances in AI, increasingly complex therapeutic modalities, and a growing demand for more predictive and translational science, researchers are rethinking every stage of the pipeline. Traditional approaches are being challenged by new expectations around speed, data integration, and real-world relevance, prompting the adoption of automated workflows, human-relevant preclinical models, and technologies capable of addressing biological complexity at unprecedented depth. Bringing together expert insight and cutting-edge developments, this curated SelectScience Accelerating Science Feature explores how these shifts are reshaping modern R&D, helping you navigate emerging approaches and stay at the forefront of drug discovery.

Navigate the key shifts shaping drug discovery by exploring each theme below.

Automation, AI, and digital technologies are redefining how drug discovery is conducted. As datasets grow in scale and complexity, researchers are moving toward more connected, data-driven environments, where automated workflows, integrated platforms, and advanced analytics enable faster decision-making and improved reproducibility across the pipeline.

At the same time, these advances are reshaping how scientists interact with data, shifting from manual, linear processes to more dynamic, end-to-end workflows that enable real-time insight and collaboration. From target identification through to preclinical development, digital transformation is helping to break down silos, streamline operations, and unlock new efficiencies, ultimately accelerating the pace and precision of modern drug discovery.

Despite advances in preclinical science, traditional models often struggle to fully capture the complexity of human disease, creating a disconnect between early-stage findings and clinical outcomes. In response, a new generation of human-relevant models is emerging, designed to better reflect physiological systems and provide more meaningful insight into how therapies will perform in the real world.

From organoids and microphysiological systems to advanced in vitro platforms, these approaches are reshaping how researchers study disease, evaluate efficacy, and assess safety. As adoption grows, they are not only improving the predictive power of preclinical research, but also helping to bridge the gap between discovery and translation, supporting more confident decision-making across the drug discovery continuum.

Advanced therapeutic modalities are reshaping what is possible in drug discovery. Moving beyond traditional small molecules, approaches such as mRNA, cell and gene therapies, and targeted protein degradation are opening up new ways to intervene in disease, enabling more precise, programmable, and personalized treatments.

This shift is expanding not only what can be targeted, but how therapies are designed, delivered, and evaluated. As a result, researchers are navigating increasing complexity across the pipeline, from understanding mechanism of action to ensuring consistency, scalability, and real-world effectiveness. Rather than fitting into established workflows, these modalities are driving the need for new frameworks, where discovery, characterization, and development are more closely interconnected. Technologies and analytical strategies must evolve in parallel, supporting deeper insight into structure, function, and performance at every stage. Together, these advances are redefining progress across the drug discovery continuum, helping to translate cutting-edge innovation into therapies with the potential to address increasingly complex and previously untreatable diseases.

Never miss an update

Stay informed as the drug discovery and development landscape continues to evolve. Become a free SelectScience member today to receive the latest news, expert insights, and updates delivered straight to your inbox. Join a global community of professionals and ensure you never miss critical updates in this rapidly changing field.

What is the SelectScience Accelerating Science in Drug Discovery feature?

The SelectScience Accelerating Science in Drug Discovery feature is a global editorial initiative exploring the technologies, approaches, and scientific advances reshaping modern pharmaceutical R&D. The feature focuses on key shifts across the drug discovery continuum, from AI-enabled workflows and human-relevant preclinical models to emerging therapeutic modalities such as mRNA, cell and gene therapies, and targeted protein degradation.

Why is SelectScience launching the feature?

Drug discovery is undergoing rapid transformation, driven by increasing biological complexity, advances in digital technologies, and the emergence of new therapeutic classes. At the same time, there is growing pressure to improve efficiency, predictability, and translational success. The Accelerating Science in Drug Discovery feature has been developed to provide clear, expert-led insight into these changes, helping scientists and industry professionals understand and navigate the evolving R&D landscape.

Who is the feature designed for?

The feature is designed for scientists and professionals working across drug discovery and development, including:

• Pharmaceutical and biotech researchers
• Preclinical and translational scientists
• Laboratory leaders and R&D decision-makers
• Technology specialists and platform developers
• Academic researchers involved in drug discovery

What key topics does the feature cover?

The feature focuses on three core areas driving change across drug discovery:

• Tools and trends driving pharma innovation – including automation, AI, and digital transformation
• Human-relevant preclinical models – enabling more predictive and translational research
• Advanced therapeutic modalities – such as mRNA, cell and gene therapies, and targeted protein degradation

How does the feature reflect changes across the drug discovery continuum?

The feature explores how innovation is reshaping every stage of the drug discovery continuum, from early research and target identification through to preclinical development and therapeutic design. By connecting advances in workflows, models, and modalities, it highlights how traditionally separate areas of R&D are becoming increasingly integrated.

Which technologies and approaches are highlighted?

SelectScience highlights enabling technologies and strategies supporting modern drug discovery, including:

• AI-driven data analysis and digital laboratory workflows
• High-throughput and automated experimentation
• Advanced in vitro and organoid-based model systems
• Analytical and characterization tools for complex biologics and gene therapies
• Platforms supporting modality development, delivery, and scale-up

What types of content are included?

The feature brings together a curated selection of high-value resources, including:

• Editorial articles and expert insights
• Application notes and technical resources
• Industry perspectives and opinion pieces
• Product and technology highlights
• Curated feature pages and content collections

How does the Accelerating Science in Drug Discovery feature support real-world drug discovery workflows?

The content is designed to provide practical insight into how emerging technologies and approaches can be applied across real R&D environments. It explores how scientists are adapting workflows, integrating new tools, and adopting innovative models and modalities to improve outcomes, reduce risk, and accelerate progress.

How can professionals engage with the feature?

Professionals can explore the Accelerating Science in Drug Discovery feature by accessing curated content across each topic area, discovering expert perspectives, and engaging with the latest developments through SelectScience’s ongoing editorial coverage.